{"filing":{"accession_number":"0001213900-26-097891","cik":"0001611747","ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ea0304833-6k_scinai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390026097891/ea0304833-6k_scinai.htm"},"events":[{"id":31883,"run_id":29282,"accession_number":"0001213900-26-097891","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Scinai announced the conclusion of its option and license arrangements with PinCell regarding PC111 and a strategic refocusing of R\u0026D resources toward its NanoAb platform and CDMO business. This is a material portfolio restructuring decision affecting the company's strategic direction and capital allocation, but does not fit neatly into specific event categories (not an M\u0026A termination, not a workforce reduction, not a specific financial event). The decision to exit PC111 and reallocate resources is an operational/strategic business event that would affect a reasonable investor's assessment of the company's future prospects and capital deployment.","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34912,"accession_number":"0001213900-26-097891","item_number":"EX-99.1","item_title":"ea030483301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Scinai announced the conclusion of its option and license arrangements with PinCell regarding PC111 and a strategic refocusing of R\u0026D resources toward its NanoAb platform and CDMO business. This is a material portfolio restructuring decision affecting the company's strategic direction and capital allocation, but does not fit neatly into specific event categories (not an M\u0026A termination, not a workforce reduction, not a specific financial event). The decision to exit PC111 and reallocate resources is an operational/strategic business event that would affect a reasonable investor's assessment of the company's future prospects and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:55:38.179534+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34912,"accession_number":"0001213900-26-097891","item_number":"EX-99.1","item_title":"ea030483301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Scinai announced the conclusion of its option and license arrangements with PinCell regarding PC111 and a strategic refocusing of R\u0026D resources toward its NanoAb platform and CDMO business. This is a material portfolio restructuring decision affecting the company's strategic direction and capital allocation, but does not fit neatly into specific event categories (not an M\u0026A termination, not a workforce reduction, not a specific financial event). The decision to exit PC111 and reallocate resources is an operational/strategic business event that would affect a reasonable investor's assessment of the company's future prospects and capital deployment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T13:55:38.179534+00:00","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-09-08"}]}